Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 12/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32686876 | 0.93 | TNIK (0.36) | TNIKMETNPC1MIFALDH1A1 | |
| SCHEMBL32686731 | 0.90 | MIF (0.39) | TNIKNPC1MIFALDH1A1LMNA | |
| SCHEMBL32686871 | 0.90 | NPC1 (0.39) | TNIKNPC1MIFALDH1A1LMNA | |
| SCHEMBL32686806 | 0.90 | NPC1 (0.39) | TNIKNPC1MIFALDH1A1LMNA | |
| SCHEMBL32686845 | 0.90 | NPC1 (0.39) | TNIKNPC1MIFALDH1A1LMNA | |
| SCHEMBL32686743 | 0.89 | TNIK (0.41) | TNIKMETMIFLMNASMN1; SMN2 | |
| SCHEMBL31667652 | 0.88 | NPC1 (0.46) | TNIKNPC1MIFALDH1A1LMNA | |
| SCHEMBL31667553 | 0.88 | TNIK (0.32) | TNIKNPC1MIF | |
| SCHEMBL32686828 | 0.88 | TNIK (0.32) | TNIKNPC1MIF | |
| SCHEMBL32686874 | 0.87 | SIGMAR1 (0.41) | TNIKNPC1MIFPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | TNIK 4286/4885MET 2688/4885NPC1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.